Clinical trial
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced…
NCT00038051 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038051 |
|---|---|
| Title | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies |
| Official title | Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Disorders, Anemia, Refractory, With Excess of Blasts |
| Intervention type | Drug |
| Interventions | Hum-195/rGel |
| Enrollment | 28 |
| Start date | May 1, 1999 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | May 27, 2002 |
| Last update posted | Apr 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: